Related Experiment Videos
Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients
A Bertolotto1, F Gilli, A Sala
1Unità dipartimentale: Centro Riferimento Regionale Sclerosi Multipla (CReSM) and Neurobiologia Clinica, Ospedale Universitario S. Luigi Gonzaga, Orbassano, Torino, Italy. NSGLB@tin.it
Neurology
|February 26, 2003
Summary
Neutralizing antibodies (NAb) can reduce or abolish the bioavailability of interferon-beta (IFNbeta) in multiple sclerosis (MS) patients. Early detection of non-responsive patients is crucial for effective MS treatment strategies.
Area of Science:
- Immunology
- Neuroscience
- Pharmacology
Background:
- MxA protein is an antiviral marker induced by type I interferons (IFN).
- MxA gene expression serves as a key indicator for assessing the biological activity of exogenous interferon-beta (IFNbeta).
Purpose of the Study:
- To quantify MxA mRNA levels in patients with multiple sclerosis (MS) undergoing IFNbeta therapy.
- To investigate the impact of neutralizing antibodies (NAb) on IFNbeta bioavailability and treatment response in MS patients.
Main Methods:
- Quantitative-competitive PCR was employed to measure MxA mRNA in peripheral blood mononuclear cells.
- IFNbeta-induced neutralizing antibodies (NAb) were assessed using a cytopathic effect assay.
- Patients were categorized into NAb-negative, persistent NAb-positive, and isolated NAb-positive groups.
Main Results:
- IFNbeta-treated patients showed significantly higher MxA mRNA levels compared to treatment-naïve patients.
- A substantial percentage of patients with elevated NAb titers exhibited reduced or abolished MxA mRNA induction, indicating diminished IFNbeta bioavailability.
- Patients with isolated NAb+ or NAb-negative status maintained comparable IFNbeta bioavailability.
Conclusions:
- Neutralizing antibodies (NAb) significantly impair IFNbeta bioavailability in a relevant proportion of MS patients.
- Monitoring MxA mRNA levels and NAb status can aid in identifying non-responsive MS patients early.
- These findings support personalized treatment adjustments for MS patients receiving IFNbeta therapy.